Bausch Health's $2B pursuit of Xifaxan successor hits wall with phase 3 failure
23rd January 2026 Uncategorised 0A potential inflection point that Bausch Health hoped could diversify its portfolio has vanished with a pair of phase 3 failures for a new formulation of the company’s bread-and-butter Xifaxan—a setback that leaves a $2 billion hole in its growth plan.
More: Bausch Health's B pursuit of Xifaxan successor hits wall with phase 3 failure
Source: fierce